P2.16-10 Advances in Diagnosis and Treatment of Non-Small Cell Lung Cancer Are Translating into Real-World Survival Gains in the United States

Abstract

Background: The last two decades have been notable for advances in the histologic and molecular classification of non-small cell lung cancer (NSCLC) as well as the introduction of new cytotoxic agents, targeted therapies and immunotherapy into the routine care of metastatic NSCLC based on clinical trial results. We sought to evaluate temporal trends in overall survival (OS) among unselected patients with metastatic NSCLC in the United States (US). Method: We utilized the Surveillance, Epidemiology, and End Results (SEER) 9 registries in identifying patients with new diagnoses of stage IV NSCLC. Staging was based on the American Joint Committee on Cancer (AJCC) 3 rd and 6 th edition staging guidelines for the periods